Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To compare the survival benefit of microwave ablation plus recombinant human Endostatin (Endostar) with microwave ablation alone in patients with inoperable stage I non small cell lung cancer

Trial Profile

To compare the survival benefit of microwave ablation plus recombinant human Endostatin (Endostar) with microwave ablation alone in patients with inoperable stage I non small cell lung cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Endostatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Primary endpoint (Overall Survival) has not been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 07 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top